Russian Military Medical Academy ReportsRussian Military Medical Academy Reports2713-23152713-2323Eco-Vector4340010.17816/rmmar43400Research ArticleIMMUNOLOGICAL FEATURES OF YERSINIOUS COLITS AND INFLAMMATORY DISEASES OF THE INTESTINE. MECHANISM OF THEIR POSSIBLE ASSOCIATIONSorokinA. N-S.M. Kirov Military Medical Academy of the Ministry of Defense13122020391S15816028082020Copyright © 2020, Sorokin A.N.2020Nflammatory bowel disease (IBD) is a disease with not fully understood triggering factors. Lack of sufficient knowledge about the mechanisms of disease development inhibits the development of a scientifically based management strategy for patients with IBD. There is insufficient evidence of yersiniosis in IBD. In the course of work, the immunological features of IBD and infectious colitis caused by Y. pseudotuberculosis and Y. enterocolitica were studied. An analysis was made of the clinical and immunological features of UC, CD, and yersiniosis colitis based on the data from the case histories of two groups of patients. The work uses the results of an in-depth study of case histories of 78 patients with IBD. Data are presented on the presence of changes in the quantitative composition of Th2 lymphocytes, changes in the quantitative and qualitative composition of the intestinal microflora in patients with IBD. The inflammatory process after infectious colitis caused by Yersinia opens the door to the development of chronic inflammation, that is, the development of IBD. An analysis was made of the clinical and immunological features of UC, CD, and yersiniosis colitis based on the data from the case histories of two groups of patients. The results were compared with the analysis of scientific literature on the research topic. Among patients with IBD who have a history of the disease “yersiniosis colitis” (16 patients), only 10 have positive PCR results for intestinal yersiniosis. Thus, the development mechanism of IBD is a complex, multifaceted process, which involves many etiopathogenetic factors that overlap and complement each other.MALDI-TOFinflammatory bowel diseaseintestinal yersiniosisulcerative colitisPCRMALDI-TOFTh2 lymphocytesвоспалительные заболевания кишечникакишечный иерсиниозязвенный колитПЦРTh2-лимфоциты[1. Белоусова, Е.А. Язвенный колит и болезнь Крона / Е.А. Белоусова. - Тверь: Изд-во «Триада», 2002. - 128 с.][2. Власенко, A.A. Биологические методы лечения как новая ступень эволюции терапии воспалительных заболеваний кишечника / A.A. Власенко, Е.В. Сушкова, Г.Р. Бикбавова, С.В. Полторака // Омский научный вестник. - 2009. - №1(84). - С.37-41.][3. Ивашкин В.Т. Основные понятия и положения фундаментальной иммунологии / В.Т. Ивашкин // Российский журнал гастроэнтероло-гии, гепатологии, колопроктологии. - 2008. - Т.4. - С.4-14.][4. Ивашкин, В.Т. Местный иммунитет и микробиоценоз при заболеваниях кишечника / В.Т. Ивашкин, H.JI. Денисов // Российский жур-нал гастроэнтерологии, гепатологии, колопроктологии. - 2009. - №6. - С.11-16.][5. Шестакова, И.В. Иерсиниоз: расширяя традиционные представления о диагностике, лечении и диспансеризации больных / И.В. Шестакова, Н.Д. Ющук // Лечащий врач. - 2010. - №10. - С.26-33.][6. Ющук, Н.Д. Иерсиниозы / Н.Д. Ющук, Г.Я. Ценева, Г.Н. Кареткина, Л.Е. Бродов. - М., Медицина, 2003. - 178 с.][7. Bernstein, C.N. Geographical variability and environmental risk factors in inflammatory bowel disease / C.N. Bernstein, M.H. Vatn, P.L. Lakatos, E.V. Loftus Jr. // Gut. - 2013. - Vol.62, №4. - P.630-649.][8. Walczak, A. The lL-8 and IL-13 gene polymorphisms in inflammatory bowel disease and colorectal cancer / A. Walczak, K. Przybylowska, L. Dziki [et al.] // DNA Cell Biol. - 2012. - Vol.31, №8. - P.1431-1438.][9. Yang, X. Genetically determined differences in IL-10 and IFN-g responses correlate with clearence of Chlamidia trachomatis mous pneu-monitis infection / X. Yang, K.T. HayGlass, R.С. Brunham // J. Immunol. - 1996. - Vol.156. - P.4338.]